Guide price only. Final cost is confirmed after assessment.
Ostenil Injection offers a cutting-edge approach to managing joint pain associated with osteoarthritis. At London Cartilage Clinic, we utilise this hyaluronic acid-based treatment to provide relief and improve joint function for our patients, ensuring an enhanced quality of life.
Reviewed byProfessor Paul Lee MBBch, FRCS (Tr & Orth), PhDCartilage and joint preservation expertise
Ostenil replenishes hyaluronic acid in arthritic joints to improve lubrication, absorb load, and reduce painful friction during movement.
It is typically considered as part of an overall osteoarthritis management strategy including activity modification and rehabilitation.
The value of Ostenil depends on precise indication and injection technique. Our team focuses on making sure the right patient receives the right product at the right time.
At London Cartilage Clinic, Ostenil is delivered within a comprehensive joint-care pathway focused on practical pain relief, function, and long-term joint preservation.
The relief from Ostenil Injection can last for several months, varying from patient to patient. Its long-lasting effect is one of the key benefits of this treatment.
Ostenil Injection is effective in various joints affected by osteoarthritis, not just the knee. It’s important to consult with our specialists to determine the best treatment plan for your condition.
Ostenil Injection is generally well-tolerated, with minimal risks. Any potential side effects or concerns can be discussed during your consultation with our experts.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
Cartilage requires no blood vessels—movement is its nutrient supply. Weight-bearing compresses the joint; unloading draws fresh synovial fluid inward, delivering oxygen and glucose to cartilage cells. Prolonged immobilisation reverses this, accelerating damage. Physiotherapy harnesses this mechanical cycle to slow structural decline, though it cannot regenerate tissue already lost.
Cartilage defects larger than 2–4 cm² exceed microfracture's scope. ACI generates hyaline-like tissue with type II collagen, whilst microfracture produces fibrocartilage with type I collagen, which is mechanically inferior and degrades within two to three years.
Hip cartilage cannot repair itself—it lacks blood vessels. ChondroFiller, a type I collagen scaffold injected under ultrasound, enables progenitor cells to rebuild tissue as the scaffold gradually biodegrades.
